Healx
Updates
News
Latest news posts
4 February 2020
Healx appoints Dr Anthony Hall as Chief Medical Officer
Cambridge, UK – 4 February 2020 – Healx, the AI-powered and patient-inspired technology company specialising in finding new treatments for rare diseases, today announced the appointment of Dr Anthony Hall, MB BS BSc, as Chief Medical Officer (CMO). Tony will be responsible for progressing the company’s rare disease drug candidates through the clinic, with an … Continued
20 December 2019
Q&As Webinar: The Rare Treatment Accelerator
The Rare Treatment Accelerator is a global partnering programme that gives patient groups and Healx the opportunity to work together to quickly discover and develop repurposed treatments for rare diseases using AI. We have committed a total of $20 million over the next two years towards finding new treatments – investing up to the value … Continued
4 February 2020
Cambridge, UK – 4 February 2020 – Healx, the AI-powered and patient-inspired technology company specialising in finding new treatments for rare diseases, today announced the appointment of Dr Anthony Hall, MB BS BSc, as Chief Medical Officer (CMO). Tony will be responsible for progressing the company’s rare disease drug candidates through the clinic, with an … Continued
20 December 2019
The Rare Treatment Accelerator is a global partnering programme that gives patient groups and Healx the opportunity to work together to quickly discover and develop repurposed treatments for rare diseases using AI. We have committed a total of $20 million over the next two years towards finding new treatments – investing up to the value … Continued
9 December 2019
Cambridge, UK – 9 December 2019 – Healx the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases. The project will leverage Healx’s comprehensive AI-based drug discovery platform, Healnet, and expertise in rare diseases and … Continued
21 November 2019
Cambridge, UK – 21 November 2019 – Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that applications are now being accepted for its Rare Treatment Accelerator (RTA). The programme focuses on finding new treatments for rare diseases by partnering with selected rare disease patient groups to leverage the … Continued
5 November 2019
Michale has been featured in recognition of her contribution to Healx’s business through the negotiation and closing of the company’s first pharma deals, navigating new issues such as data use and IP in drug discovery deals using artificial intelligence (AI). In addition to this, Michale has been instrumental in developing Healx’s business activities through two … Continued
1 November 2019
Poster #1: Deep Bidirectional Transformers for Relation Extraction without Supervision NLP Scientist, Yannis Papanikolaou, will be presenting his work on relationship extraction, using a fine-tuning of Google’s BERT language model. Being able to successfully extract relationships despite scarce data is vital to discovering treatments for rare diseases, for which funds – and therefore research – … Continued
16 October 2019
Cambridge, UK – 16 October, 2019 – Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that it has raised $56 million in a Series B financing round, led by one of Europe’s largest VC firms Atomico and joined by Intel Capital, Global Brain and btov Partners. All previous … Continued
3 October 2019
We are delighted to announce a collaboration with scientists at the Institute of Cancer Research (ICR) to discover new possible ways of treating diffuse intrinsic pontine glioma (DIPG), a life-limiting childhood brain cancer for which no treatments currently exist. The ICR is an internationally-renowned research centre in the study of childhood cancers, including in DIPG, … Continued
11 July 2019
We are pleased to announce the appointment of Neil Thompson, PhD, as Chief Scientific Officer (CSO). Neil will spearhead the expansion of the drug discovery and development team at Healx, as the company continues its growth as a leading AI-powered, next-generation biopharmaceutical company. Healx is pioneering in that it takes a patient-first approach and integrates … Continued
28 February 2019
Healx (healx.io), today announced a partnership with Boston Children’s Hospital and Barth Syndrome Foundation (BSF) to advance promising therapeutic compounds using a novel approach that will accelerate drug discovery for applications in Barth syndrome